LB Pharmaceuticals, a CNS-focused biotech, has filed for an initial public offering (IPO) targeting up to $228.5 million, with an option to raise up to $263.4 million by offering 16.7 million shares at an assumed price of $15 per share3.
Proceeds from the IPO will fund a Phase III trial for LB-102, an oral small molecule antipsychotic developed as a modified version of amisulpride, targeting acute schizophrenia135.
LB-102 demonstrated statistically significant efficacy and tolerability in a Phase II study, leading to plans for FDA discussions after potential Phase III success13.
LB also intends to use IPO funds for a Phase II trial in bipolar depression, beginning in Q1 2026 alongside the Phase III schizophrenia trial (both FDA-approved designs)4.
The drug, protected by intellectual property through 2037, aims to address limitations of existing therapies (side effects and efficacy) in the estimated $15 billion U.S. antipsychotic market23.
Future expansion plans include Alzheimer's psychosis and a long-acting injectable formulation to further extend the reach of LB-10224.
LB's IPO is notable as the first major biotech public offering filed after a six-month drought in the sector, and is seen as a crucial financial lifeline given the company’s limited cash reserves145.
Sources:
1. https://www.renaissancecapital.com/IPO-Center/News/112984/LB-Pharmaceuticals-prepares-to-break-the-biotech-IPO-dry-spell
2. https://www.ainvest.com/news/lb-pharmaceuticals-100m-ipo-strategic-play-cns-therapeutics-intellectual-property-driven-biotech-growth-2508/
3. https://www.fiercebiotech.com/biotech/lb-pharmaceuticals-eyes-228m-ipo-fund-late-stage-schizophrenia-study
4. https://www.ifre.com/equities/2305022/lb-pharma-reaches-for-ipo-lifeline
5. https://medcitynews.com/2025/08/schizophrenia-drug-lb-pharmaceuticals-biotech-ipo-amisulpride-antipsychotic-lbrx/